There are better ways to do this, man

Two years ago, Ben Bartch was a third-string tight end at D-III St. Johns University in Minnesota. His coaches didnt see a path to consistent playing time at his current position but they liked his blocking ability, so they suggested he add some weight to his 6' 6", 250-pound frame and start playing offensive line.

The position switch was life-changing for Bartch, who has gone from D-III backup to legitimate NFL prospect. He weighed in at 309 pounds this week at the combine in Indianapolis, and the story of how he packed on all that weight is truly harrowing.

Bartch told reporters in Indy on Wednesday that he would consume a frightening combination of foods just to up his caloric intake.

Heres the recipe:

Bartch then combined all the ingredients in a blender and choked down his improvised protein shake.

I would just throw it all in and then plug my nose, Bartch said. In the dark. I would gag sometimes. Thats what you have to do sometimes.

Without access to the nutritionists big-time programs have, Bartch resorted to using the internet to figure out how he could gain weight quickly and safely.

I just kind of researched online for the most clean and healthy ingredients for putting on good mass, Bartch said. That summer I went from 250 (pounds) to 275, and then after that I went from 275 to 305.

Did any of that research say you had to blend everything together, though? A breakfast of scrambled eggs with grits, cottage cheese and a peanut butter-banana sandwich on the side, washed down with Gatorade sounds decent enough. Putting it all together in one protein-packed slurry just sounds like a nightmare. It must have looked as disgusting as it tasted, especially if he used a brightly dyed Gatorade flavor like fruit punch or orange.

As horrifying as it may have been, forcing himself to consume the concoction has propelled Bartch to a likely spot in the NFL. Once hes in the pros, hell have a whole team of nutrition advisers who can help him maintain a healthy weight without drinking things that make him want to barf.

The Hartford womens basketball team entered Wednesdays season finale winless (028, 015 in America East play). Picking up their first victory of the season in their last shot would be a tough task for the Hawks, who were playing the best team in their conference, Stony Brook (252, 131 in-conference).

But Hartford pulled off the massive upset, 7067, and avoided becoming the only team in Division I (mens or womens) to go winless this season.

It was first-year Hartford head coach Morgan Valleys first career victory, and her old coach Geno Auriemma was thrilled to hear about it.

The strange story of a plot to steal a rare baseball card from a sports bar. ... Meet the camp counselors who keep the NFL combine running smoothly. ...The Celtics Jayson Tatum has exploded into superstar status this season. ... Pavel Francouz traveled a long road to finally become a full-time NHL goalie at age 29.

A congressional committee wants to stop ticket sellers from adding so many surprise fees. ... David Ortiz is holding an estate sale,and his 2002-model HP printer is up for grabs. ... Time Tebow is going to represent the Philippines in World Baseball Classic qualifying. ... Many Kobe Bryant items have been pulled from eBay because the site prohibits profiting off of human tragedy or suffering.... A Texas woman stole Rockets owner Tilman Fertittas identity and was approved for a credit card. ... One of YouTubes most popular NBA highlight pages got nuked.

Earths orbit has captured a second moon. ... Conditions for Uber and Lyft drivers at LAX are truly abominable. ... This comedian wrote a funny diary about what happens when a tweet goes mega-viral.

Email dan.gartland@si.com with any feedback or follow me on Twitter for approximately one half-decent baseball joke per week. Bookmark this page to see previous editions of Hot Clicks and find the newest edition every day. By popular request Ive made a Spotify playlist of the music featured here. Visit our Extra Mustard page throughout each day for more offbeat sports stories.

Read the original:
D-III Draft Prospect Ben Bartch Drank an Unholy Concoction to Pack on 60 Pounds - Sports Illustrated

Diana Portillo, For the Headlight Published 11:49 a.m. MT Feb. 27, 2020

Portillo(Photo: Courtesy photo)

Maintaining adequate physical activity can positively impact many different areas of our lives.Of course, we all know that exercise in conjunction with a healthy diet is critical to attaining and maintaining healthy weight, but there are many other benefits to exercising.

Exercise assists in the prevention and management of chronic health conditions like high blood pressure, diabetes, and hyperlipidemia (high cholesterol). Bone health can also be improved by exercising and it is recommended for the treatment and prevention of osteoarthritis and osteoporosis.

Studies show that routinely engaging in exercise is beneficial to mental wellness and helps in coping with anxiety, depression, stress management, and post-traumatic stress disorder (PTSD).

Some of the daily benefits of implementing exercise may include increased energy levels, improved gastrointestinal mobility (decreased constipation), improvement in sleep, as well as improvement in cognition and mental alertness.

In addition to the benefits one gets from exercising, those who engage in group physical activity such as Zumba, dance fitness, CrossFit, or swim aerobic classes also have the opportunity to socialize with otherswhich, in itself, has many benefits for general well being.

Line dancing is a good way to build cardio-vascular health as a form of intermediate exercise activity.(Photo: Bill Armendariz - Headlight Photo,)

The U.S. Department of Health and Human Services has broken down the recommended amount of exercise that one should participate in into different age and condition categories. Children and adolescents need one hour or more of daily physical activity. For the recommended hour a day there should be a combination of aerobic, muscle strengthening, and bone-strengthening activities mixed throughout the week.

Healthy adults should be engaging in 150-300 minutes of moderate-intensity, or 75-150 minutes of vigorous-intensity, physical activity a week. Adults should engage in at least 2 or more days of muscle strengthening, focusing on the major muscle groups of the body.

Older adults, if able to, should engage in 150 minutes of physical activity a week. This should encompass balance-training, muscle strengthening, and aerobic activity. The elderly need to consider their current fitness ability and chronic conditions when choosing how much and what type of exercise to engage in.

Adults with chronic conditions should follow the recommendations for adults when able to. For the elderly and adults with chronic conditions which prevent them from engaging in exercise, efforts should be made to avoid inactivity and they should work with their healthcare provider to find activities they can safely engage in without putting them at risk of injury.

There are many different physical activities one can engage in for exercise. Consideration of current physical activity and personal preference can assist a person in deciding what activity would be better suited for them to engage in. Here are a few examples of exercise:

Walking

Chair exercise using items in the house (bottles of water, cans of food, books, towels, etc.) to add resistance or assist in movement training

Dancing at home

Yoga

Tai Chi

Group exercises like Zumba, Jazzercise, CrossFit, spinning, and dance fitness

Bike riding

Swimming

Running

Weight lifting

Kick boxing

It is essential to know your limitations when starting to exercise or increasing your current physical activity routine. Starting off with low intensity and slowly increasing physical activity as tolerated is important to avoiding injury and early burnout.

If you are not sure if you are physically capable of engaging in exercise, or would like further recommendations on where to start, schedule an appointment with your healthcare provider who can assist you and recommend activities that will fit your current physical ability.

Information contained in this article should not replace treatment and management of acute and chronic conditions by a licensed healthcare provider.

Gila Regional Medical Center (GRMC) is a 68-bed acute care facility located in Silver City, NM. GRMC has outpatient family medicine clinics and specialty care clinics throughout Luna and Grant County ready to meet the medical needs of the communities they serve.

Diana Portillo is aDNP (Doctorate of Nursing Practice) FNP-C, PMHNP-BC, Family and Psychiatric Mental Health Nurse Practitioner atGila Regional Family Medicine in Deming, NM.

Read or Share this story: https://www.demingheadlight.com/story/news/2020/02/27/health-beat-get-moving-benefits-and-recommendations-exercise/4884149002/

Link:
Health beat: Get moving! The benefits and recommendations for exercise - The Deming Headlight

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the fourth quarter and full year 2019.

The FDA approval of PALFORZIA was a defining moment for the peanut allergy community and Aimmune, and a culmination of years of commitment to bring an approved treatment to people with potentially life-threatening peanut allergy. We are thrilled to have achieved the first regulatory approval for a therapy for peanut allergy in fact, for any food allergy, said Jayson Dallas, M.D., President and CEO of Aimmune Therapeutics. We are now focused on PALFORZIA launch execution, which is well underway. Our field commercial team is engaging with allergists to help them learn how to safely incorporate PALFORZIA into their practices, and our market access team has begun its work to secure formulary access for PALFORZIA. We are encouraged by the amount of early interest we have received from allergists who want to offer PALFORZIA to their patients. We also are delighted with the funding we received from Nestle Health Science and KKR, which bolster both our commercial and development endeavors, including the addition of AIMab7195 to our pipeline.

PALFORZIA Highlights:

Ongoing Clinical Trials to Expand Pipeline and Support CODIT Platform:

Corporate Highlights:

Upcoming Milestones

1Q 2020

Roll-out of U.S. launch of PALFORZIA following FDA approval in January 2020 (ongoing)

4Q

2020

Expected European Medicines Agency (EMA) action date for MAA of PALFORZIA for peanut allergy in children and adolescents ages 4 to 17 years

H2

2020

Expected completion of enrollment of POSEIDON phase 3 clinical trial

H1

2021

Expected completion of AR201 phase 2 clinical trial for egg allergy

Mid-

2021

Expected completion of Swissmedic review of PALFORZIA for marketing authorization in Switzerland

Fourth Quarter and Full Year 2019 Financial Results

For the fourth quarter and year ended December 31, 2019, net loss was $66.9 million and $248.5 million, respectively, compared to net loss of $57.0 million and $210.8 million, respectively, for the comparable periods in 2018. On a per share basis, net loss for the quarter and year ended December 31, 2019, was $1.06 and $3.97, respectively, compared to net loss per share of $0.95 and $3.67, respectively, for the comparable periods in 2018. The weighted average shares outstanding for the quarter and year ended December 31, 2019, were 63.2 million and 62.6 million shares, respectively, compared to 59.8 million and 57.4 million shares, respectively, for the comparable periods in 2018.

Research and development expenses for the quarter and year ended December 31, 2019 were $30.1 million and $124.0 million, respectively, compared to $33.0 million and $133.4 million, respectively, for the comparable periods in 2018. The decrease was primarily due to lower external clinical-related expenses, partially offset by increases in regulatory, quality and manufacturing expenses.

General and administrative expenses for the quarter and year ended December 31, 2019 were $36.9 million and $125.8 million, respectively, compared to $25.4 million and $81.9 million, respectively, for the comparable periods in 2018. The increase was primarily due to increased external professional services costs, employee-related costs and facilities and other costs related to medical affairs and the preparations for commercial launch.

Cash, cash equivalents, and investments totaled $158.2 million on December 31, 2019, compared to $303.9 million on December 31, 2018. The decrease primarily reflects net cash used in operating activities, partially offset by cash provided by financing activities, including net borrowings from our debt issuance in January 2019 of $36.1 million. In February 2020, we borrowed an additional $85.0 million under our debt agreement with KKR, and Nestl Health Sciences invested an additional $200.0 million in the company.

Conference Call Details

In connection with this announcement, Aimmune Therapeutics will host a conference call and webcast today at 4:30 p.m. ET. To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 4527099. To access a live or recorded webcast of the call, please visit the Investor Relations section of the Aimmune Therapeutics website at http://www.aimmune.com. The recorded webcast will be available for approximately 30 days following the call.

About AIMab7195

AIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcRIIb). IgE recognizes and interacts with allergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response in patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two phase 1 studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease.

In February 2020, Aimmune licensed exclusive worldwide rights to Xencors XmAb7195 for the development of next-generation food allergy treatments.

About AR201

AR201 is an investigational biological drug in phase 2 clinical development for use in oral immunotherapy for egg allergy. Academic studies of the oral immunotherapy approach for egg allergy treatment have shown efficacy, and Aimmune is studying this more broadly with AR201 in order to enable widespread availability of a potential treatment.

About PALFORZIA

PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and older. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. PALFORZIA is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

INDICATION

PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older.

PALFORZIA is to be used in conjunction with a peanut-avoidant diet.

Limitations of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

IMPORTANT SAFETY INFORMATION

Boxed WARNING:

PALFORZIA can cause anaphylaxis, which may be life threatening and can occur at any time during PALFORZIA therapy.

Prescribe injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.

Do not administer PALFORZIA to patients with uncontrolled asthma.

Dose modifications may be necessary following an anaphylactic reaction.

Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dosing level, for at least 60 minutes.

PALFORZIA is available only through a restricted program called the PALFORZIA REMS.

CONTRAINDICATIONS

PALFORZIA is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal disease.

WARNINGS AND PRECAUTIONS

Anaphylaxis

PALFORZIA can cause anaphylaxis, which may be life threatening. PALFORZIA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the PALFORZIA REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer PALFORZIA.

Anaphylaxis has been reported during all phases of PALFORZIA dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures.

Do not initiate PALFORZIA treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. PALFORZIA may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including but not limited to markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, PALFORZIA may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine.

All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered in a certified health care setting.

Patients may be more likely to experience allergic reactions following PALFORZIA administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding PALFORZIA temporarily.

Asthma

Uncontrolled asthma is a risk factor for a serious outcome, including death, in anaphylaxis. Ensure patients with asthma have their asthma under control prior to initiation of PALFORZIA.

PALFORZIA should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of PALFORZIA should be undertaken cautiously. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of PALFORZIA.

Eosinophilic Gastrointestinal Disease

Discontinue PALFORZIA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain.

Gastrointestinal Adverse Reactions

Gastrointestinal adverse reactions were commonly reported in PALFORZIA-treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms consider a diagnosis of eosinophilic esophagitis.

ADVERSE REACTIONS

The most common adverse events reported in subjects treated with PALFORZIA (incidence 5% and 5% than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, pruritus, urticaria, anaphylactic reaction, and ear pruritus.

Please see full Prescribing Information, including Boxed WARNING, and Medication Guide at http://www.PALFORZIA.com.

For more information about PALFORZIA, please call 1-844-PALFORZ (1-844-725-3679) or visit http://www.PALFORZIA.com.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. For more information, please visit http://www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmunes expectations regarding the potential benefits of PALFORZIA, AR201 and AIMab7195; Aimmunes expectations regarding the commercial launch of PALFORZIA; Aimmunes expectations regarding the timing of a potential acceptance and applicable review period of the MAA for AR101 by the EMA and by Swissmedic; Aimmunes expectations on the timing of completing a phase 2 clinical trial for AR201; Aimmunes expectations on the planned timing for the announcement of the completion of the POSEIDON clinical trial for PALFORZIA; Aimmunes expectations on the mechanisms of action of AIMab7195; Aimmunes expectations regarding the timing and availability of the full amount of proceeds under its loan agreement with KKR; Aimmunes expectations regarding the sufficiency of its cash resources; and Aimmunes expectations regarding potential applications of the CODIT approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the satisfaction of closing conditions for each tranche of its loan agreement; Aimmunes or any of its collaborative partners ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmunes or any of its collaborative partners clinical trials will not be successful; Aimmunes dependence on the success of PALFORZIA; Aimmunes reliance on third parties for the manufacture of Aimmunes products and product candidates; possible regulatory developments in the United States and foreign countries; and Aimmunes ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns PALFORZIA, which has been approved for marketing in the United States by the FDA; AR101, a product candidate that is under clinical investigation in Europe; AR201, a product candidate under clinical investigation in the United States; and AIMab7195, a product candidate that Aimmune expects will be under clinical investigation. AR201 and AIMab7195 have not been approved for marketing by the FDA, the EMA or Swissmedic. AR101, in Europe, AR201 and AIMab7195 are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

PALFORZIA, AIMMUNE, AIMMUNE THERAPEUTICS and CODIT are trademarks of Aimmune Therapeutics, Inc.

References

i United States Census Bureau Quick Facts (2015 estimates)ii Gupta R, Warren C, Blumenstock J, et al. OR078 The Prevalence of Childhood Food Allergy in the United States: An Update. Ann Allergy Asthma Immunol. 2017;119(5 Suppl): S11.iiiAmerican College of Allergy, Asthma & Immunology. Available here: https://acaai.org/allergies/types/food-allergies/types-food-allergy/peanut-allergy. Accessed December 20, 2019.iv Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018;142(6):e20181235.v As reviewed in Burks, Sampson, Plaut et al. Treatment for Food Allergy. Journal Allergy Clin Immunol (2018)

AIMMUNE THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

December 31,2019

See more here:
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights - Business Wire

Weve all got that friend who gave up dairy and says it totally saved their skin. Its a tale so common in beauty circles that dairy is widely regarded as public enemy number one when it comes to our complexion. Whether its eczema, acne, or simply the dullness that accompanies unhealthy skin, apparently dairy has an awful lot to answer for.

According to the Vegan Society, the number of vegans in the UK has quadrupled in the last six years, with almost 600,000 of us avoiding dairy (and meat, of course) in pursuit of improved health, boosted energy levels and better skin. Oat milk is now de rigueur on breakfast menus, dairy-free cheese is stocked by local supermarkets, and ice cream is just as nice made with cashew nuts rather than cream. When it comes to our diet, we have options galore but does giving up dairy in pursuit of better skin actually make it so?

Read more: How Acne Patches Became The New Pimple Paste

While its been suggested that dairy products play a role in developing skin conditions, such as acne, the current evidence is actually very limited and conflicting, says Dr Megan Rossi, a dietitian and gut health specialist. Its important to note that most of the studies done so far are observational studies, which can be a useful place to start, but are pretty weak in terms of take-home messages. In fact, there are a number of variables that could be affecting the results it could be that people who drink more milk eat less dietary fibre and more added sugars. These types of stats make it impossible to determine if one thing causes the other, she adds.

Facialist Debbie Thomas asks her clients who suffer with acne to consider both diet and lifestyle. Yes, dairy can be a trigger to some, but not all acne is caused by it, she says. However, acne is usually more likely to be caused by sugar, stress thats sending hormones loopy, or underlying conditions, like polycystic ovary syndrome.

Both experts acknowledge that reports of dairys effect on the skin arent totally unfounded rather, that its impact has not been scientifically proven by a solid number of studies. Remember that acne is a condition you have and spots are the end result of whats being triggered by the reactions within the body so its important to work out, on an individual basis, what triggers your skin, says Thomas. Both experts advise keeping a food diary to track skin triggers and make links between your own diet and skin health.

Below, four things to know about dairy and how it relates to our skin.

We know that our hormones can impact our skin the spots that can appear at certain points in our menstrual cycle provide monthly anecdotal evidence of this. What we eat (and, of course, how we live) can affect our hormones, too. Cows milk and dairy products contain casein and whey protein, which are thought to raise levels of a certain hormone (insulin-like growth factor-1, or IGF-1) which is linked with increased production of sebum, the oily substance produced by our skin, which is, in turn, linked with acne development, says Rossi. Some studies have shown that people with acne have higher levels of the IGF-1 hormone. A link has been drawn between a high sugar, dairy and carb diet and increased incidence of acne in the western world, but as Rossi points out, a clinical trial is yet to have shown that dairy alone causes skin issues.

Dairy alone isnt the only foodstuff that can impact our hormones other foods, when combined with dairy products (like milk) can leave them out of whack, too. Milk, combined with other processed foods and sugar, disrupts insulin levels, pushing other hormones out of balance; because when we digest milk we break down the proteins it contains, turning them into hormones that are very similar to insulin, Thomas says. The higher our insulin levels, the more susceptible we are to infection, and the more inflammation our bodies suffer cue more breakouts and angry skin. Inflammatory skin conditions include, most commonly, acne, eczema, and rosacea, says Thomas. If the inflammation is present in the body as a long-term issue, it will eventually reach the skin, which results in a breakdown of collagen, faster appearance of fine lines and compromised skin health.

Read more: Are You Following The Right Skincare Regime For Your Age?

Lactoses in milk need enzymes to break them down, says Rossi. About 65 per cent of people lose these enzymes when they pass infancy. When were older, the body develops an intolerance or allergy to the lactose, which triggers an inflammatory reaction within the body. Of course, some of us are more intolerant than others, and if you suffer from any symptoms like bloating, nausea or flatulence Rossi recommends trying her three-step Record, Restrict, Retintroduce assessment (found in her book Eat Yourself Healthy) to find out if you could have a food intolerance safely and effectively.

If youre considering quitting all dairy in pursuit of better skin, know that not all cow produce is created equal. A 2019 study found that there was some association between overall milk consumption and acne, particularly for those consuming a lot of it. Interestingly, the relationship of acne with different types of milk whole, semi-skimmed or low fat and skimmed varied, with skimmed milk having the highest [negative] impact on the skin, says Rossi. Fermented dairy, on the other hand, has not been found to increase the risk of acne, so consider things like yoghurt and (hallelujah!) cheese, your friends, rather than enemies. Furthermore, fermented dairy, such as kefir and live yoghurt, has been linked with better heart and bone health, plus improved digestion and weight management, she points out. So perhaps, as with all good things in life, its about opting for moderation and balance, rather than total dairy abstinence.

More from British Vogue:

All products featured on the website are independently selected by our Editors. However, when you buy something through our retail links, we may earn an affiliate commission.

Go here to read the rest:
The Confusing Truth About Dairy And How It Really Affects Your Skin - British Vogue

Following are some of the best foods to eat on the keto diet, along with their serving sizes and an explanation of why theyre good for people following this eating approach.

Per 1 tablespoon (tbsp) serving:124 calories, 0g net carbs, 0g protein, 14g fat

Benefits:This is a good source of heart-healthy monounsaturated fatty acids.

Per 1 tbsp serving:124 calories, 0g net carbs, 0g protein, 14g fat

Benefits:Researchhasshown that consumption of canola oil can reduce total and bad cholesterol.(3)

Per 1 tbsp serving:116 calories, 0g net carbs, 0g protein, 14g fat

Benefits:While high in saturated fat, coconut oil mayincrease good HDL cholesterollevels.

Per 1 tbsp serving:115 calories, 0g net carbs, 0g protein, 14g fat

Benefits:Derived from coconut, MCT stands for medium chain triglycerides.Limited research suggestsMCT oil may aid in weight loss and help promote ketosis.

Per 1 tbsp serving:100 calories, 0g net carbs, 0g protein, 11g fat

Benefits:Though the serving provides 11g of saturated fat,researchhas found that butter wasnt a major factor in increasing risk of chronic conditions, like heart disease or diabetes. (4)

Per 1 slice serving:113 calories, 0g net carbs, 7g protein, 9g fat

Benefits:Cheese is allowed as you please, but cheddar is a good example of its nutrition stats. One studyfound that cheese eaters had a 12 percent lower risk of type 2 diabetes. (5)

Per 1 tbsp serving:52 calories, 0g netcarbs, 0g protein, 5g fat

Benefits:This is an easy way to add calories and fat into aketogenicdiet.

Per 1 slice serving:43 calories, 0g net carbs, 3g protein, 3g fat

Benefits:The green light on bacon may be one reason youre up for sticking to the diet, as it can make eating occasions more palatable. Just watch the sodium content, as it can add up quickly.

Per 1 thigh serving:318 calories, 0g netcarbs, 32g protein, 20g fat

Benefits:Leave the skin on here for extra fat. One thigh is a good source of selenium, zinc, and B vitamins.

Per 1 egg serving:77 calories, 1g net carbs, 6g protein, 5g fat

Benefits:Eggs contains the perfect duo of satiating protein and fat; theyre also high in the antioxidant mineral selenium.

Per 3-ounce (oz) serving (measured raw):279 calories, 0g net carbs, 12g protein, 24g fat

Benefits:Ground beef (made with 70 percent lean meat and 30 percent fat) is a higher-fat choice but thats the point here. Youll also get an excellent source of vitamin B12, which is necessary to keep energy levels up.

Per 3-oz serving:224 calories, 0g net carbs, 22g protein, 14g fat

Benefits:Youll get an impressive amount of muscle-building protein plus satiating fat in this option. Its also rich in zinc, a mineral that promotes proper thyroid functioning.

Per 1 cup (raw) serving:27 calories, 2g netcarbs, 3g protein, 0g fat

Benefits:Asparagus contains bone-building calcium, plus other minerals, such as potassium and magnesium, which has been linked with blood sugar regulation.

Per avocado serving:160 calories, 2g net carbs, 2g protein, 15g fat

Benefits:The creamy fruits are packed with fiber, something that you may lack on the keto diet. They also are an excellent source of immune-revvingvitamin C.

Follow this link:
The Keto Diet: 7-Day Menu and Comprehensive Food List ...